Decipher Biosciences Inc. (Decipher) is a genomic classifier (GC) that could help estimate the risk of distant metastasis (DM) after radical prostatectomy in patients with prostate cancer. The effectiveness of the classifier is...
Recent studies have shown that adding tislelizumab, a humanized monoclonal antibody directed against PD-1, to standard chemotherapy can improve outcomes in patients with advanced squamous non-small-cell lung cancer (NSCLC). This...
Combination therapy of weekly lzomib, lenalidomide, dexamethasone is used for patients with newly diagnosed multiple myeloma. Recent studies show that adding daratumumab to this weekly dosing can increase the safety and efficacy...
Stereotactic body radiotherapy (SBRT) has shown positive outcomes in improving survival among patients with oligometastases. However, not many studies have analyzed its safety and efficacy in treating patients with multiple...
Among vulnerable older patients with ovarian cancer, single-agent carboplatin is proposed instead of conventional carboplatin-paclitaxel doublet therapy. The effects of this approach on patients have not been well-studies. This...
PD-1 immune checkpoint blockade and cytokine IL-33 have shown significant therapeutic effects in tumor immunotherapy. These therapies promote CD8 T cell activation, proliferation, and effector functions. However, there were few...
The immune checkpoint molecule PD-L1 (CD274) is a crucial regulator of the tumor immune response. Its expression has been reported in the therapeutic context in Head and Neck Squamous Cell Carcinoma (HNSCC), but it remains...
Anal squamous cell carcinoma has rarely reported in ulcerative colitis.Understand the prognosis of anal squamous cell carcinoma in the setting of ulcerative colitis.Retrospective review.Referral center.Adult patients with both...
Acquired cystic disease (ACD) associated renal cell carcinoma (RCC) is designated as a new subtype unique to patients with end-stage renal disease (ESRD) according to the 2016 World Health Organization (WHO) classification....
Combined axitinib and immuno-oncology (IO) therapy is approved for first-line advanced renal cell carcinoma. Overlapping toxicities represent a clinical challenge. Calculating the time to resolution (TTR) of common...
The increasing demands for personalized targeted therapy directed against Renal Cell Carcinoma has driven a search for predictive markers. Novel therapies targeting HIF-1α in Renal Cell Carcinoma have been developed and HIF-1α...
Prostate cancer is a major health concern in males worldwide, owing to its high incidence. Sparstolonin B (SsnB), a component of the Chinese herbal medicine Sparganium stoloniferum, is used to treat many diseases. However, the...
